What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2025-02-21 compared with 2024-02-16 · 30 added, 36 removed, 53 unchanged (55% of the section changed)

9 unchanged sentences

District Court for the Northern District of Illinois.

In addition, in December 2021, a purported class of Canadian preterm infants filed suit in British Columbia and, in October 2022, a purported class of Israeli preterm infants filed suit in Tel Aviv, both of which make similar allegations as those made in the United States against Abbott.

In addition, in December 2021, a purported class of Canadian preterm infants filed suit in British Columbia that makes similar allegations as those made in the United States against Abbott.

These plaintiffs seek various damages.

In January 2024, the Israeli lawsuit was dismissed without prejudice.

Many of the lawsuits name another infant formula manufacturer as a co-defendant.

In June and July 2021, DexCom, Inc.

(DexCom) initiated patent infringement litigation against Abbott over certain of Abbott's continuous glucose monitoring products, including those under the FreeStyle brand, in the U.S.

District Court for the Eastern District of Texas and in the Regional Court of Mannheim in Germany.

In both jurisdictions, DexCom seeks injunctive relief and monetary damages.

In all cases, Abbott asserts that it has a license to each of Dexcom' s asserted patents and that the patents are invalid and not infringed.

In July 2021, Abbott sued DexCom for patent infringement over certain of DexCom’s continuous glucose monitoring products in the U.S.

District Court for the District of Delaware, the Regional Courts of Mannheim and Dusseldorf in Germany, and the High Court of Justice in the United Kingdom.

Abbott seeks injunctive relief and monetary damages.

In December 2021, Abbott filed a breach of contract suit against DexCom in the U.S.

District Court for the District of Delaware alleging that DexCom breached the parties' 2014 Settlement and License Agreement by asserting infringement of patents against Abbott that DexCom previously licensed to Abbott.

In July 2023, Abbott was found to have a license to certain of DexCom’s patents in Abbott’s breach of contract suit.

In November 2023, the U.S.

Patent and Trademark Office found some of DexCom’s asserted patent claims invalid.

Throughout 2023, Abbott and DexCom filed additional patent infringement actions in the U.S., Germany, the U.K., Spain, and the Unified Patent Court.

DexCom’s first U.S.

patent infringement trial on its remaining claims is scheduled for March 2025.

Abbott’s first U.S.

patent infringement trial against DexCom is scheduled for March 2024.

In a trial held in July 2024, a jury in a Missouri state court awarded a plaintiff $495 million in damages.

Abbott stands by its products and the information it provided about them, and it appealed this jury’s verdict with the Missouri Court of Appeals in December 2024.

In a trial held in October 2024 involving Abbott and another infant formula manufacturer and the treating hospital as co-defendants, a jury in a Missouri state court returned a unanimous verdict for Abbott and its co-defendants.

In December 2024, the plaintiff filed a motion for a new trial.

As previously disclosed, DexCom, Inc.

(Dexcom) and Abbott filed various patent infringement actions against each other over certain of the other company’s continuous glucose monitoring products in the U.S., Germany, the U.K, Spain, and the Unified Patent Court, which litigation commenced in 2021.

In December 2024, Abbott reached an agreement with Dexcom to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.

The agreement will result in the dismissal of all pending cases in courts and patent offices worldwide.

In November 2022, Abbott learned that the United States Department of Justice, through the United States Attorney’s Office for the Western District of Michigan, is conducting a criminal investigation related to Abbott’s manufacturing of infant formula.

In December 2022, Abbott received a subpoena from the Enforcement Division of the Commission requesting information relating to Abbott’s powder infant formula business and related public disclosures.

In January 2023, Abbott received a civil investigative demand from the United States Federal Trade Commission seeking information in connection with its investigation of companies who participate in bids for Women, Infants, and Children infant formula contracts.

In addition, multiple civil lawsuits have been filed against Abbott relating to Abbott’s manufacturing of certain powder infant formula products.

Six shareholder derivative lawsuits against certain of Abbott’s current and former directors and officers are pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation , in the U.S.

District Court for the Northern District of Illinois.

The consolidated lawsuit seeks monetary damages from the defendants to Abbott.

In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation includes:

DiNapoli, Controller of the State of New York, as Administrative Head of the New York State and Local Retirement System, and as Trustee of the New York State Common Retirement Fund, and International Brotherhood of Teamsters Local No.

710 Pension Fund and Southeastern Pennsylvania Transportation Authority, both filed in June 2023;

David Hamilton filed in April 2023;

Matthew Steele filed in February 2023;

Ilene Lippman filed in January 2023;

and Leon Martin filed in October 2022.

In August 2024, the court granted in part and denied in part the defendants’ motion to dismiss, allowing the securities and breach of fiduciary duty claims to move forward.

In September 2024, Abbott’s board of directors established an independent and disinterested special litigation committee to investigate and evaluate the asserted claims.

In November 2024, the special litigation committee filed a motion to stay the case in order to conduct its investigation.

In February 2025, the court granted in part and denied in part the committee's motion, allowing written discovery to proceed.

MINE SAFETY DISCLOSURES

3 unchanged sentences

Each executive officer holds office until a successor has been duly elected or appointed and qualified or until the officer’s death, resignation, or removal.

Vacancies may be filled at any time by the board.

Vacancies may be filled at any time by the board of directors.

Any executive officer may be removed by the board of directors when, in its judgment, removal would serve the best interests of Abbott.

6 unchanged sentences

2018 to 2020 — President and Chief Operating Officer, and Director since 2019.

2015 to 2018 — Executive Vice President, Medical Devices.

Elected Corporate Officer — 2008.

1 unchanged sentence

Elected Corporate Officer — 2012.

2024 to present — Executive Vice President, Finance a nd Chief Financial Officer.

2023 to 2024 — Senior Vice President, Finance a nd Chief Financial Officer.

2020 to 2023 — Vice President, Finance a nd Controller.

2017 to 2020 — Divisional Vice President, Controller, Medical Devices.

Elected Corporate Officer — 2020 .

Earnhardt, 55

1 unchanged sentence

2019 to 2023 — Executive Vice President, Medical Devices.

2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing treatments for ear, nose and throat conditions).

Elected Corporate Officer — 2019.

Funck, Jr., 62

2023 to present — Executive Vice President, Finance.

2020 to 2023 — Executive Vice President, Finance and Chief Financial Officer.

2018 to 2020 — Senior Vice President, Finance and Controller.

2013 to 2018 — Vice President, Controller.

Elected Corporate Officer — 2005.

2019 to present — Executive Vice President, Human Resources.

2013 to 2019 — Divisional Vice President, Compensation, Benefits and HR M&A.

Elected Corporate Officer — 2019.

9 unchanged sentences

2019 to present — Executive Vice President, Rapid and Molecular Diagnostics.

2015 to 2019 — Vice President, Molecular Diagnostics.

Elected Corporate Officer — 2015.

2023 to present — Senior Vice President, Finance a nd Chief Financial Officer.

2020 to 2023 — Vice President, Finance a nd Controller.

2017 to 2020 — Divisional Vice President, Controller, Medical Devices.

Elected Corporate Officer — 2020 .

McCoy, Jr., 55

4 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings